September 9: The Week in Cancer News
Early-onset cancer is increasing globally, testing population-wide preventive DNA testing, and more from the week in cancer news.
Progress Against Cancer
Early-onset cancer is increasing globally, testing population-wide preventive DNA testing, and more from the week in cancer news.
The immune checkpoint inhibitor durvalumab was approved in combination with chemotherapy for certain biliary tract cancers that have spread. The U.S. Food and Drug Administration (FDA) has approved durvalumab (Imfinzi) in combination with the...
Fertility preservation does not impact outcomes for breast cancer patients, and ultraprocessed foods linked to increased risk of colorectal cancer in men.
Advanced cervical cancer rates are rising despite prevention and screening tools and more from the week in cancer news, selected by the editors of Cancer Today.
An inhibitor of the growth-stimulating FGFR1 protein was approved for patients with a rare type of blood cancer. The U.S. Food and Drug Administration (FDA) has approved pemigatinib (Pemazyre) for adult patients with relapsed...
Link found between fracking wells and leukemia in children, and more from this week in cancer news.
Sometimes referred to as stage 0 breast cancer, ductal carcinoma in situ (DCIS) is a noninvasive growth of abnormal cells within the breast’s milk ducts. More than 50,000 cases of DCIS are diagnosed each...
Drug for HER2-positive cancer receives further approvals, and researchers study the risk of lung cancer from wildfires.
The FDA granted accelerated approval to the first HER2-targeted therapy for the treatment of non-small cell lung cancer with activating HER2 mutations The U.S. Food and Drug Administration (FDA) has granted accelerated approval to...
The FDA approved the kinase inhibitor capmatinib for lung cancers harboring a certain mutation in the protein MET. The U.S. Food and Drug Administration (FDA) has granted full approval to capmatinib (Tabrecta) for the...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More